Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Pridinol
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Pridinol
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
WHO defined daily dose (DDD)
6 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 12 studies.
Reviews & meta-analyses: 1 · 2023–2026
Showing all 12 studies, sorted by most relevant.
Fu TC, Lane NE, Lee SH, et al.
2025
Chronic rheumatic pain disorders, including rheumatoid arthritis (1), osteoarthritis (2), fibromyalgia (3), and gout (4), represent a substantial burden on patients and healthcare systems due to their persistent nature, high prevalence, and impact on functional mobility (5). While conventional pharmacotherapy, such as disease-modifying antirheumatic drugs (DMARDs), corticosteroids, and biologic agents, remains a cornerstone of treatment, limitations in efficacy, long-term safety concerns, and potential adverse effects necessitate the exploration of adjunctive therapies (6). Consequently, there has been an increasing emphasis on rehabilitation and alternative medicine modalities (7), including evidence-based physical therapy interventions (8,9), acupuncture (10), mind-body approaches (11) such as mindfulness-based stress reduction, and integrative medicine (12)(13)(14)(15) strategies that combine conventional and complementary methodologies.To provide a structured perspective on the various studies included in thisResearch Topic, we have categorized them into three major domains: Physical Therapy and Manual Techniques, Traditional and Complementary Medicine, and Epidemiological and Research Trends. Each of these categories encapsulates a distinct approach to managing chronic rheumatic pain disorders, offering insights into evidence-based rehabilitation, integrative therapies, and research trends that shape future clinical applications.Research trends in physical therapy for knee osteoarthritis (KOA) from 2013 to 2022 identified key thematic clusters and influential contributors, with Harvard University leading contributions in the field (16). Aerobic exercise and lower limb strengthening were found to be effective, emphasizing the need for personalized exercise dosing and digital interventions to promote self-management. Future studies should incorporate rigorous trials to validate these approaches. A cross-sectional study in Poland examined occupational risk factors for nonspecific neck pain among healthcare workers, identifying prolonged static postures, ergonomic deficiencies, and psychological stress as key contributors (17). These findings highlight the need for ergonomic and rehabilitative interventions to mitigate occupational risks. Another bibliometric analysis assessed global trends in dry needling from 2004 to 2024, highlighting increasing academic interest but a lack of large-scale, high-quality trials validating its efficacy (18). A review on KOA management emphasized pharmacologic and nonpharmacologic approaches, including platelet-rich plasma (PRP), stem cell therapy, exercise, and multimodal pain management, advocating for integrative strategies to optimize patient outcomes (19). An umbrella review evaluated PRP efficacy for KOA using nine meta-analyses encompassing 46 datasets, with mixed findings regarding its effectiveness in pain relief and mobility improvement (20).Variability in PRP preparation and patient selection contributed to these inconsistencies, emphasizing the need for standardized methodologies and long-term outcome assessments. Sartori et al conducted a randomized controlled pilot trial to evaluate ultrasound-guided percutaneous peripheral nerve stimulation (pPNS) targeting the gluteal nerves in individuals with chronic knee pain. The intervention improved hip extension power, suggesting potential benefits for knee function and pain management. Further research is needed to confirm these findings (21).While promising, larger studies are needed to confirm its clinical applicability. A retrospective study assessed Pridinol Mesylate combined with rehabilitation in elderly patients with spondyloarthritis-related low back pain, showing superior pain reduction and functional improvement compared to monotherapy with either intervention alone (22). Further trials are necessary to confirm long-term efficacy. A randomized trial compared the efficacy of Extracorporeal ShockWave Therapy (ESWT) and mesotherapy for myofascial pain syndrome, concluded that ESWT provided greater pain relief and improved mobility (23). Another study evaluated high-frequency laser therapy (HFLT) for cervical disk herniation, demonstrating comparable efficacy to physiotherapy, suggesting it as a noninvasive alternative (24).These studies underscore the growing significance of evidence-based rehabilitation techniques in managing chronic pain conditions. By incorporating regenerative medicine, neuromodulatory interventions, high-frequency laser therapy, and ESWT, these approaches contribute to a comprehensive, multimodal treatment framework aimed at enhancing pain relief, restoring function, and improving overall patient well-being. The findings further highlight the necessity of rigorous clinical validation and interdisciplinary collaboration to refine and optimize rehabilitation methodologies for musculoskeletal and rheumatic disorders, ensuring their effective integration into mainstream clinical practice.A randomized trial investigated the effects of Yijinjing, a traditional Chinese exercise, on rheumatoid arthritis (RA)-related hand dysfunction, reporting significant improvements in hand mobility, grip strength, and quality of life (25). Although promising, further research is required to establish long-term efficacy and determine optimal exercise regimens. A case report explored the application of traditional Chinese manual therapy in a 10-year-old patient with adolescent idiopathic scoliosis, showing improvements in spinal alignment and pain reduction over 18 months (26).Larger studies are needed to confirm its efficacy as a conservative treatment option. A case series examined acupuncture for linezolid-induced peripheral neuropathy in multidrug-resistant tuberculosis, documenting pain relief and functional recovery (27). However, larger controlled trials are required to validate these findings. A case report integrated graded exercise with motion-style acupuncture therapy for a patient with failed back surgery syndrome and major depressive disorder. This intervention demonstrated physical and psychological improvements (28) suggesting future studies should explore if this intervention has broader applicability. A meta-analysis reviewed osteopathic craniosacral therapy (CST) for chronic pain and mobility disorders, and it demonstrated some benefits in chronic somatic pain but raising concerns about methodological rigor and placebo effects (29).These studies highlight the integration of traditional therapeutic modalities with modern rehabilitative techniques, demonstrating their potential for neuromuscular reconditioning, pain modulation, and functional improvement. By incorporating acupuncture, structured therapeutic exercise, craniosacral therapy, and manual interventions, these complementary approaches provide holistic, patient-centered treatment options for managing chronic pain and musculoskeletal disorders. While preliminary findings suggest promising benefits, further rigorous, high-quality research is essential to establish standardized protocols, validate long-term efficacy, and optimize their integration into contemporary clinical practice.As rehabilitation and alternative medicine therapies evolve, future research should focus on optimizing evidence-based integrative treatment strategies for chronic rheumatic pain disorders. Key areas for advancement include standardizing physical therapy protocols, enhancing neuromodulatory techniques, and refining traditional therapeutic modalities such as acupuncture and osteopathic manipulation. Multidisciplinary collaboration among rheumatologists, physiotherapists, and integrative medicine practitioners will be key to advancing effective and sustainable chronic pain management.and alternative medicine in the management of chronic rheumatic pain disorders. The included studies demonstrate the therapeutic potential of physical therapy, manual interventions, acupuncture, neuromodulatory approaches, and osteopathic techniques in improving pain relief, functional mobility, and quality of life. While these findings emphasize the value of multimodal, patient-centered treatment strategies, further high-quality clinical trials and interdisciplinary collaborations are necessary to establish standardized, evidence-based protocols for broader clinical application.Moving forward, an integrative, personalized approach that combines conventional and complementary therapies will be essential in addressing the complex challenges of chronic pain management, ultimately leading to more effective, holistic, and sustainable healthcare solutions.
Abstract licence: CC BY
Lorenza Lauricella, Noemi Calabrese, D. Scaturro, et al.
Frontiers in Medicine, 2025
Background: Spondylarthritis is a degenerative disease involving the intervertebral disc, vertebral bodies, and adjacent soft tissues. Treatment aims to slow disease progression and manage symptoms through an interdisciplinary approach. It can be conservative and rarely chirurgic. Objective: This study aimed to evaluate the effectiveness of a rehabilitation combined with Pridinol Mesylate in the treatment of Spondylarthritis in elderly patients in terms of pain resolution, improving disability, and quality of life. Materials and methods: = 26), who received only rehabilitation (14 women and 12 men, age 66.2 ± 3.84); and the Drug Group (DG: 32), who received only the administration of the Pridinol(18 women and 14 men, age of 66.3 ± 3.9). Results: The results show, at T1 (20 days after treatment) in the CG, statistically significant improvements for the NRS and QBPDS. In the RG, statistically significant improvements were observed only for the QBPDS scale. In the DG group, only pain improvement. At T2 (90 days after treatment), the CG showed improvements in NRS, QBPDS, and (SF-36). The RG and DG showed improvements for NRS and for QBPDS. By Bonferroni method, obtained statistically significant values for CG versus RG and for CG versus DG. No statistical significance was found between RG versus DG. Conclusion: Targeted rehabilitation treatment, combined with Pridinol Mesylate, reduced pain and improved disability in lumbar Spondylarthritis both in the short and medium term, with improved quality of life in elderly patients.
Abstract licence: CC BY
Michael A Uberall
Archives of Pharmacy & Pharmacology Research, 2024
Current guidelines recommend the preferred use of NSAIDs for the treatment of acute (low) back pain [a(L)BP] for a limited period of time, although their effects in controlled clinical trials is at best manageable and effect sizes of questionable clinical relevance.
Abstract licence: CC BY-NC
Angeles Gloria Rodríguez-Basso, S. L. Bonafede, H. Prado
Journal of chromatographic science, 2023
- Diclofenac
- Piperidines
- Chromatography, High Pressure Liquid
Polak B, Kryska A, Jaglińska K, et al.
2025
The modification of non-polar silica gel plates by aqueous-organic solvent containing sodium dodecyl sulphate was investigated. The changes that occurred in the sorbent were examined using the Raman spectroscopy technique. The abovementioned technique was also involved in the investigation of carbamazepine-SDS complexes. The approach of applying the Raman spectroscopy into the investigation of the chromatographic behavior of SDS, carbamazepine and RP-18 W sorbent was presented for the first time. The effect of sodium dodecyl sulphate, SDS, concentration on the chosen drug used in neurodegenerative disorder (sulpiride, olanzapine, carbamazepine, trazodone, clomipramine, and pridinol) retention has been investigated. Such examination for these medicines has been presented for the first time for thin-layer chromatography system. Modified the mobile phase composition has resulted in the separation of the mixture containing all compounds. To confirm micellar forming, critical micelle concentration for SDS in the applied mobile phase was determined using two techniques, i.e., conductometric and spectrophotometric with azorubine as the indicator. The effect of surfactant on the solute zone shape by means of tailing and asymmetry factors has been determined. For four of the six investigated compounds, these factors have been close to 1.0. The separation efficiency measured by the height of the theoretical plate varies from 39 to 73 μm depending on the solute investigated. The method has been optimised regarding the quantitative analysis of investigated compounds, opening up new possibilities for drug analysis. In terms of the LOD values are in the range of 0.22 µg/spot to 1.67 µg/spot, whereas LOQ values are in the range of 0.66 µg/spot to 5.07 µg/spot for olanzapine and trazodone, respectively. Furthermore, the method was also applied for the quantitative analysis of the investigated compounds in pharmaceutical preparations. Such proceedings for RP-18 W TLC system containing SDS was shown for the first time. The new method has better or comparable concentration ranges regarding some of investigated compounds to those presented previously. Additionally, for the first time, a strategy involving various techniques (TLC chromatography supported by UV- and Raman spectroscopy and conductometry) for complex analysis of the separation system was presented, inspiring potential future research directions.
Abstract licence: CC BY-NC-ND
Traczuk Adam, Jaglinska Kamila, Polak Beata
Current Issues in Pharmacy and Medical Sciences, 2023
Abstract In this work, analysis of some drugs used in the treatment of neurodegenerative disorders (sulpiride, olanzapine, carbamazepine, trazodone, clomipramine, and pridinol) was achieved through micellar electrokinetic chromatography (MEKC). The effect of surfactant (sodium dodecylsulphate), acetonitrile, and buffer pH and concentration on the solute retention was also investigated. Successful separation of all compound mixtures was obtained. The method was applied for the quantitative analysis of investigated compounds, and the LOD and LOQ were determined. The LOD values were in the range from 0.0127 mg/mL for clomipramine, to 0.1398 mg/mL for pridinol, while LOQ were in the range 0.0384 mg/mL for clomipramine, to 0.4237 for pridinol. The mode was also applied for the determination of investigated solutes in pharmaceutical prescriptions.
Abstract licence: CC BY-NC-ND
Y. Minamijima, T. Kuroda, Atsushi Okano, et al.
Journal of Veterinary Pharmacology and Therapeutics, 2025
- Muscle Relaxants, Central
- Piperidines
- Chromatography, Liquid
Redaktion Facharztmagazine
Orthopädie & Rheuma, 2025
Marwan Mahtook, M. Saadi, Saifan Alhameedawi, et al.
Review of Clinical Pharmacology and Pharmacokinetics - International Edition, 2024
Redaktion Facharztmagazine
Schmerzmedizin, 2024
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Investigational
Major interactions
1 found
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 670 interactions
ATC M03BX03
ATC M03BX53
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Pridinol
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q827515), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.